The role of SATB2, CDX2, CK7 and CK20 in differentiating primary versus metastatic ovarian carcinoma
Main Article Content
Abstract
OBJECTIVE: To find out the association of primary ovarian carcinomas (POC) and metastatic gastrointestinal carcinoma (MGC) by utilizing a panel of antibodies including Cytokeratin (CK) 7, CK20, Caudal-type Homeobox Transcription Factor-2 (CDX2), and SATB2 with their clinicopathological parameters.
METHODS: This prospective cross-sectional study was conducted from Mar, 2023 to Dec 2023 at Dow University of Health Sciences, Karachi, Pakistan. Biopsy tissue specimens from female patients over the 40 years, diagnosed with primary and metastatic ovarian carcinomas (MOC), were included. Immunohistochemistry, employing a three-tier scoring system, assessed CK7, CK20, CDX2, and SATB2 expressions. Statistical analysis was performed, utilized SPSS version 26.0 by employing Chi-Square test.
RESULTS: Over a 9-month period, 100 biopsied tissue samples were collected from patients aged 42-71 years (mean age 53.24 ± 8.03 years). Among these, 79 were POC (51% serous carcinoma, 9% mucinous carcinoma, 18% endometrioid carcinoma, and 1% clear cell carcinoma), and 21 were MGC. CK7 showed diffuse staining predominantly in POC and was absent in MGC (p < 0.001). CK20 exhibited significant focal and diffuse staining in MGC and was largely absent in POC (p = 0.005). CDX2 was significantly absent in POC and showed diffuse and focal staining in MGC (p < 0.001). SATB2 was absent in POC and displayed focal or diffuse staining in MGC (p < 0.001).
CONCLUSION: The inclusion of SATB2 in immunohistochemical panels, alongside CK7, CK20, and CDX2, improves the accuracy of diagnosing primary and metastatic ovarian carcinomas. This approach provides support in the distinction between ovarian and gastrointestinal tumors.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Work published in KMUJ is licensed under a
Creative Commons Attribution 4.0 License
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
1. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Women's Health 2019:287-99. https://doi.org/10.2147%2FIJWH.S197604
2. Arora T, Mullangi S, Lekkala MR. Ovarian Cancer. StatPearls Publishing, Treasure Island (FL). 2021.
3. De Leo A, Santini D, Ceccarelli C, Santandrea G, Palicelli A, Acquaviva G, et al. What is new on ovarian carcinoma: integrated morphologic and molecular analysis following the new 2020 World Health Organization classification of female genital tumors? Diagnostics 2021;11(4):697. https://doi.org/10.3390/diagnostics11040697
4. Vang R, Gown AM, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, et al. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 2006;19(11):1421-8. https://doi.org/10.1038/modpathol.3800698
5. Shin JH, Bae JH, Lee A, Jung C-K, Yim HW, Park J-S, et al. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. Jpn J Clin Oncol 2010;40(3):208-13. https://doi.org/10.1093/jjco/hyp150
6. Wang Y, Liu L, Yu Y. Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment. Heliyon 2023;9:e19221. https://doi.org/10.1016/j.heliyon.2023.e19221
7. Meagher NS, Wang L, Rambau PF, Intermaggio MP, Huntsman DG, Wilkens LR, et al. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Mod Pathol 2019;32(12):1834-46. https://doi.org/10.1038/s41379-019-0302-0
8. Dundr P, Singh N, Nožičková B, Němejcová K, Bártů M, Stružinská I. Primary mucinous ovarian tumors vs. ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics. Diag Pathol 2021;16(1):1-17. https://doi.org/10.1186/s13000-021-01079-2
9. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynecol Obstet 2021;155(1):61-85. https://doi.org/10.1002/ijgo.13878
10. Kubeček O, Laco J, Špaček J, Petera J, Kopecký J, Kubečková A, et al. The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review. Clin Exp Metast 2017;34(5):295-307. https://doi.org/10.1007/s10585-017-9856-8
11. Strickland S, Wasserman JK, Giassi A, Djordjevic B, Parra-Herran C. Immunohistochemistry in the diagnosis of mucinous neoplasms involving the ovary: the added value of SATB2 and biomarker discovery through protein expression database mining. Int J Gynecol Pathol 2016;35(3):191-208. https://doi.org/10.1097/PGP.0000000000000238
12. Mostafa NA, Fathi A. Validity of SATB2 in distinguishing metastatic mucinous carcinoma of colorectal origin from primary ovarian mucinous carcinoma. Egypt J Path 2020;18(1):4-9.
13. Montiel DP, Angulo KA, Cantú-de León D, Quevedo LB, Vilchis JC, Montalvo LH. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic. Ann Diag Pathol 2015;19(4):249-52. https://doi.org/10.1016/j.anndiagpath.2015.05.004
14. Aldaoud N, Erashdi M, AlKhatib S, Abdo N, Al-Mohtaseb A, Graboski-Bauer A. The utility of PAX8 and SATB2 immunohistochemical stains in distinguishing ovarian mucinous neoplasms from colonic and appendiceal mucinous neoplasm. BMC Res Notes 2019;12(770):1-6. https://doi.org/10.1186%2Fs13104-019-4816-9
15. Li Z, Roth R, Rock JB, Lehman A, Marsh WL, Suarez A, et al. Dual immunostain with SATB2 and CK20 differentiates appendiceal mucinous neoplasms from ovarian mucinous neoplasms. Am J Clin Pathol 2017;147(5):484-91. https://doi.org/10.1093/ajcp/aqx023
16. Kurnit KC, Frumovitz M. Primary mucinous ovarian cancer: options for surgery and chemotherapy. Int J Gyne Can 2022;32(11). https://doi.org/10.1136/ijgc-2022-003806
17. Nasioudis D, Albright BB, Ko EM, Haggerty AF, Giuntoli RL, Burger RA, et al. Advanced stage primary mucinous ovarian carcinoma. Where do we stand? Arch Gynecol Obstet 2020;301:1047-54. https://doi.org/10.1007/s00404-020-05489-3